a Objective: HIV interclade B superinfection has previously been described in individuals initially infected with drug resistant virus who then become superinfected by a drug susceptible strain. We report an individual initially infected with a drug-sensitive clade B strain of HIV who was superinfected with another clade B strain resistant to two classes of antiretroviral drugs.
Introduction
Superinfection with HIV is presumed to occur frequently because of the prevalence of interclade recombinants [1, 2] . However, documented superinfection in humans has only recently been reported, first with different clades and subsequently, two instances of intraclade B superinfection [3] [4] [5] [6] [7] . Koelsch et al. reported a patient who was initially infected with drug-resistant HIV and then secondarily infected by drug-sensitive ('wild-type') virus. The superinfecting wild-type HIV replicated at high levels and masked from standard drug resistance tests the underlying presence of the initial drug-resistant virus [4] .
We now report a patient initially infected with a drugsensitive clade B strain of HIV who was superinfected with another clade B strain resistant to two important classes of antiretroviral drugs.
Case report
In September 2001, a 31-year-old man was enrolled into the San Diego Acute HIV Infection and Early Disease Research Program (AIEDRP) after recently testing positive for HIV at a community clinic. He previously Initially, the patient's HIV VL remained low (140-2927 copies/ml) until 260 days after presentation when it increased to 11 611 copies/ml. It continued to increase to 142 566 copies/ml 4 months later, which corresponded to a drop in CD4 cell count to 331 Â /l (Fig. 1) 
Methods
Clonal env sequencing HIV RNA was isolated from the subject's blood plasma from two time-points 228 days apart (11 September 2001, 29 April 2002) using the QIAamp Viral RNA extraction kit (QIAGEN Inc., Valencia, California, USA) according to manufacturer's instructions. Nested PCR of the V3 coding region was performed using previously described primers and methods [4] . PCR products were cloned using TOPO Cloning vectors (Invitrogen Corporation, Carlsbad, California, USA) per the manufacturer's instructions. Fifteen clones were sequenced using dye terminator sequencing and analyzed using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, California, USA).
Phylogenetic analysis of pol and env sequences Sequences were initially compiled, aligned, and edited in BioEdit using CLUSTAL W alignment tool. The alignment was then manually edited to preserve frame insertions and deletions. Phylogenetic analyses were performed using Phylogeny Inference Package software (PHYLIP) and FastDNAml (J. Felsenstein, 1993. PHYLIP version 3.5c. University of Washington, Seattle; G. Olsen, University of Illinois) starting from a neighborjoining tree using the previously measured parameters from the maximum likelihood tree. To evaluate for possible sample contamination sequences from standard lab strains were included in the phylogenetic analysis.
Length polymorphism analysis
The V4-5 coding region of the env gene from HIV RNA was amplified by a nested PCR using previously described primers and protocols [4] . These fluorescently labeled PCR products were separated by capillary electrophoresis using an automated sequencer (ABI PRISM 3100) and analyzed by GeneScan Analysis Software (Applied Biosystems, Foster City, California, USA). These experiments were performed in triplicate.
Dye-primer sequencing
From HIV RNA isolated from blood plasma, a 500-base region of the pol gene was sequenced using ABI PRISM BigDye Primer v.3.0 kits with À20 M13 and M13 primers (Applied Biosystems, Foster City, California, USA) according to the manufacturer's protocols. Base mixtures were determined from ABI trace files using Vector NTI v.5.0 (InforMax, Frederick, Maryland, USA). Values from forward and reverse strand sequencing were averaged and correlated with those obtained from control samples [9] .
Results
HIV superinfection was suspected when retrospective drug resistance testing (260 days after enrollment into the AIEDRP cohort) on previously collected samples detected acquisition of resistance to protease inhibitors, to which the patient was never exposed. In retrospect, this switch in drug susceptibility occurred 4 months before the subject entered the treatment trial and in conjunction with a rise in plasma HIV RNA and drop in CD4 cell count. Both viral isolates were clade B. To discriminate superinfection or coinfection from the selection of drug resistance, cloning of the V3 region of HIV envelope was performed on samples collected before and after the emergence of drug resistance. Phylogenetic reconstruction revealed no intermingling of sequences between the two time-points, and genetic distances between the two clusters of sequences were greater then 10% (Fig. 2a) , indicating two epidemiologically distinct strains [10] [11] [12] .
To distinguish further between coinfection and superinfection, length polymorphism detection (GeneScan) of the V4-5 region of HIV envelope from HIV RNA extracted from blood samples collected at the two time-points (September 2001 and April 2002) was also performed. The assay can discern minority variants that make up 1-5% of the viral population [4, 13] . The viral populations differed by a two-codon (six-base pair) insertion in the region at the second time-point with homogenous populations at both time-points (data not shown). To further confirm the superinfection, dyeprimer sequencing of a 500-base pair fragment of the HIV pol, which spanned the 184 region of reverse transcriptase, was also performed. This method is reported to detect a minor variant that makes up as little as 5-10% of the total viral population [4, 9] . In the two samples obtained before the genotypic switch ( (Fig. 2b) .
Replication capacity (RC) of the viral isolates using a pol sequence in a recombinant assay also changed between time-points [14] . The first virus had an RC of 57%, while the second virus had an RC of 18%, which is consistent with the presence of the M184V mutation and protease mutations [14, 15] . At the next time-point (13 August 2002) when the 184V mutation had reverted to 184M, the RC was 63% even though the protease mutations remained. This change in RC did not explain the rise in VL seen after the second HIV infection, suggesting viral fitness based on HIV genes outside of the pol coding region.
Discussion
Although unlikely, it is possible that the individual described in this report was coinfected with both a drug susceptible and drug resistant strain and that the drug resistant strain only emerged at a later time. However, four independent lines of molecular investigation: env cloning, sequencing, and phylogenetic analysis; dyeprimer sequencing; length polymorphism detection; and pol sequencing and phylogenetic analysis provide evidence that the individual was initially infected with wild-type HIV and subsequently superinfected with a second strain resistant to two classes of antiretroviral drugs, nucleoside reverse transcriptase inhibitors and protease inhibitors. He maintained relatively good control of the first virus, with low HIV VL and high CD4 cell counts, without antiretroviral therapy. He subsequently experienced a rise in VL and a drop in CD4 cell count coincident with the appearance of the second virus, which is similar to previous reports of superinfection [4, 16] . The greater fitness of the second virus in this individual, demonstrated by its predominance in vivo, was not supported by the replication capacity assay of the viral isolates. The replication capacity assay only interrogates (or assesses) replication fitness contributed by the pol coding region, while other genes such as env most likely play an important role in determining in vivo fitness of the virus [15] .
This superinfection negatively affected this subject's disease and course of treatment. It was not known that he had acquired a drug-resistant virus before he entered the trial for treatment-naive patients. During the ACTG 5095 trial, he received the combination therapy of zidovudine, lamivudine, and abacavir and his VL decreased from 65 954 copies/ml to 263 copies/ml, but never became undetectable (Fig. 1 ). This incomplete response may have resulted from the patient's intermittent compliance with his medications secondary to nausea during the trial or it may have been that the prescribed treatment regimen was suboptimal since there was unrecognized reduced susceptibility to two of the medications used (M184V mutation in reverse transcriptase).
This first observation of superinfection with multidrugresistant virus was initially recognized as a failure of antiretroviral therapy, which raises the possibility that some patients who fail antiretroviral therapy might do so because of superinfection rather than the de novo evolution of drug resistance. At present, it appears unlikely that superinfection contributes substantially to a significant number of cases of drug resistance in clinical practice since a recent retrospective study by Gonzalez et al. comparing viral sequences from patients undergoing serial resistance genotyping found no evidence for such cases. However, it is unclear whether any baseline viral sequences were compared in that study [12] .
HIV drug resistance acquired through superinfection significantly lowers the likelihood of successful antiretroviral therapy. It undermines the clinical value of a patient's prior drug resistance testing and lack of prior antiretroviral use. Vigilant personal protection, through safe sex practices or clean needle use for injection drugs, must be counseled to patients already infected with HIV even if their risk exposures are with other HIV infected people.
